- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04583488
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
November 16, 2023 updated by: Johns Hopkins University
A Phase I Study of Intraperitoneal Docetaxel in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) for Gastric Cancer Patients With Peritoneal Carcinomatosis
This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Gastric cancer (GC) is one of the leading causes of cancer-related deaths in the United States and has a five-year survival of 40% after surgical resection.
Metastatic gastric cancer has an even poorer prognosis and most patients die within the first year of diagnosis.
Most patients are diagnosed in advanced stages of the disease due to non-specific or lack of symptomatology and treatment options are then limited to systemic chemotherapy.
The peritoneum is the most frequent site of metastasis as well as cancer recurrence.
Peritoneal Carcinomatosis (PC) results in adverse clinical sequelae and is ultimately responsible for 60% of all gastric cancer-related deaths.
While visceral metastases originating from primary gastric cancer are relatively chemosensitive, peritoneal carcinomatosis is particularly challenging to treat because of inadequate drug delivery from systemic circulation.
The primary purpose of this trial is to determine the safety of administering intraperitoneal docetaxel in conjunction with the standard of care treatment regimen of intravenous mFOLFOX6 (5-Fluorouracil, leucovorin, and oxaliplatin) in patients with primary gastric cancer with gross peritoneal carcinomatosis.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fabian M Johnston, MD, MHS
- Phone Number: 410-502-0197
- Email: fjohnst4@jhmi.edu
Study Contact Backup
- Name: Sherry Leung
- Phone Number: 410-955-7518
- Email: sleung7@jhu.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Recruiting
- Johns Hopkins University
-
Contact:
- Fabian M Johnston, M.D., M.H.S., F.A.C.S
- Phone Number: 410-502-2846
- Email: fjohnst4@jhmi.edu
-
Contact:
- Sherry G Leung
- Phone Number: 410-955-7518
- Email: sleung7@jhu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have histologically-confirmed GC-PC by diagnostic laparoscopy who have not undergone chemotherapy for metastatic/recurrent disease.
- Be willing and able to provide written informed consent/assent for the trial.
- Be ≥ 18 years of age on day of signing informed consent.
- Not have distant metastases as ruled out by an initial imaging (e.g. CT Chest/Abdomen/Pelvis with contrast), positron emission tomography (PET scan). Any metastasis in distant organs other than the peritoneum will exclude the patient from this study.
- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale at study entry.
- Demonstrate adequate organ function. All screening labs should be performed within 7 days prior to protocol therapy.
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- Willingness to undergo intraperitoneal port placement
Exclusion Criteria:
- Has gastric cancer involving the distal esophagus above the gastroesophageal (GE) junction (Siewart type 1, proximally), or second portion of the duodenum (distally).
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
- Has a tumor positive for human epidermal growth factor receptor 2 (HER2) staining.
- Has had prior surgery with dense intra-abdominal adhesions
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks (6 weeks for nitrosureas or mitomycin C) prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Has an active infection requiring antibiotic therapy.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Has any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C virus (e.g., Hepatitis C virus RNA [qualitative] is detected).
- Patients receiving any medications or substances that are inhibitors or inducers of Cytochrome P450 3A4 (CYP 3A4) are ineligible. Investigator can change to a similar agent that is a non-CYP3A4 inhibitor/inducer with a washout period of 1 week.
- Patients with known hypersensitivity to any of the components of docetaxel or mFOLFOX6.
- Patients who received pelvic or abdominal radiotherapy.
- Peripheral neuropathy ≥ Grade 2.
- History of allogeneic transplant.
- Any known cardiac abnormalities, in accordance with mFOLFOX6 guidelines.
- Any other condition that would render the patient to be unfit for the trial as deemed by the PI or clinical team.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intraperitoneal docetaxel
Participants will receive intraperitoneal docetaxel combined with the standard of care.
A standard 3 + 3 dose escalation design will be used according to the dose escalation plan.
|
Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 20 weeks
|
To determine the Maximum Tolerated Dose (MTD) of intraperitoneal docetaxel in conjunction with the standard of care treatment regimen of intravenous mFOLFOX6 in patients with primary gastric cancer with gross peritoneal carcinomatosis
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival
Time Frame: 20 weeks
|
Progression-free survival rate at 20 weeks, which is defined as the percentage of patients alive and free of disease progression at 20 weeks.
|
20 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fabian M Johnston, MD, MHS, Johns Hopkins University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2020
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
October 5, 2020
First Submitted That Met QC Criteria
October 5, 2020
First Posted (Actual)
October 12, 2020
Study Record Updates
Last Update Posted (Estimated)
November 17, 2023
Last Update Submitted That Met QC Criteria
November 16, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Peritoneal Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Abdominal Neoplasms
- Stomach Neoplasms
- Carcinoma
- Peritoneal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
Other Study ID Numbers
- IRB00162730
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Carcinomatosis
-
Association Francaise de ChirurgieCompletedCarcinomatosis, PeritonealFrance
-
Hasselt UniversityZiekenhuis Oost-LimburgUnknownColorectal Peritoneal CarcinomatosisBelgium
-
Hospices Civils de LyonUnknownColorectal Peritoneal CarcinomatosisFrance
-
University of California, IrvineRecruitingPeritoneal Carcinomatosis | Gastrointestinal Peritoneal CarcinomatosisUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedPatients With Gastric Peritoneal CarcinomatosisFrance
-
Hospices Civils de LyonCompletedDigestive Peritoneal CarcinomatosisFrance
-
Uppsala UniversityCompletedColorectal Peritoneal CarcinomatosisSweden
-
AIO-Studien-gGmbHNeovii BiotechCompletedGastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal CarcinomatosisGermany
-
M.D. Anderson Cancer CenterCompletedPeritoneal CancerUnited States
-
Carlos ChanInstitute of Quantitative Systems Pharmacology (IQSP)RecruitingPeritoneal CarcinomatosisUnited States
Clinical Trials on Intraperitoneal docetaxel
-
The University of Hong KongTaiho Pharmaceutical Co., Ltd.CompletedGastric Cancer | Peritoneal CarcinomatosisChina
-
University of PittsburghSanofiCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Fudan UniversityUnknownStomach Neoplasms | Peritoneal MetastasisChina
-
Asan Medical CenterCompletedStage IV Gastric Cancer With MetastasisKorea, Republic of
-
Tata Memorial CentreRecruitingColorectal Cancer | Ovarian Cancer | Peritoneal DiseaseIndia
-
Guangdong Provincial Hospital of Traditional Chinese...UnknownStage IV Gastric Cancer With Metastasis | Hyperthermic Intraperitoneal Chemotherapy | Exploratory BehaviorChina
-
Shanghai East HospitalNot yet recruiting
-
Imperial College Healthcare NHS TrustNot yet recruitingHernia, Abdominal | Peritoneal Dialysis | Kidney Failure, ChronicUnited Kingdom
-
The Affiliated Hospital of Qingdao UniversityThe First Affiliated Hospital of Nanchang University; Wuhan University; Peking... and other collaboratorsRecruiting
-
Universitätsmedizin MannheimHeidelberg UniversityTerminatedAdenocarcinoma | Stomach NeoplasmsGermany